(PharmaNewsWire.Com, January 11, 2019 ) Apoptosis is a form of programmed cell death or cellular suicide. Apoptosis-susceptible cells are used in early-stage lung cancer diagnostics for the treatment of cytotoxic cancer. The agents of early-stage lung cancer diagnostics interact with the targeted cell to induce cell death. Early-stage lung cancer diagnostics has the ability to engage with the cancer cell. Early-stage lung cancer diagnostics works on the coupling phenomenon of drug-target interaction. The drug-target phenomenon of early-stage lung cancer diagnostics is the key factor behind the accuracy of the treatment. A few patients may show dramatic side-effects after undergoing cancer treatment with early-stage lung cancer diagnostics.
Early-Stage Lung Cancer Diagnostics Market: Drivers and Restraints
The rising prevalence of leukemia and prostate cancer is the primary factor driving the growth of the Early-Stage Lung Cancer Diagnostics Market. Increasing funding by governments for the development of novel therapies for the treatment of cancer is expected to boost the early-stage lung cancer diagnostics market over the forecast period even more. Additionally, the rising focus of pharmaceutical companies on launching improved drugs for the treatment of cancer is also expected to fuel the growth of the early-stage lung cancer diagnostics over the next decade. Also, a surge in the treatment adoption in developing countries is anticipated to boost the revenue of the early-stage lung cancer diagnostics market.
On the other hand, the high cost of drugs may hamper the growth of the early-stage lung cancer diagnostics market to some extent. Moreover, the lack of awareness about the advanced therapies for cancer treatment among people is also expected to deter the growth of the early-stage lung cancer diagnostics market over the forecast period.
Early-Stage Lung Cancer Diagnostics Market: Segmentation
Tentatively, the global early-stage lung cancer diagnostics market can be segmented on the basis of drug type, application, distribution channel, and geography.
Based on drug type, the global early-stage lung cancer diagnostics market is segmented as:
Polyketides Deferoxamine Mesylate Heavy Metal Antagonists Threonine Protein Phosphatases Others Based on application, the early-stage lung cancer diagnostics market is segmented as:
Prostate Cancer Brain Cancer Breast Cancer Leukemia Others Based on distribution channel, the early-stage lung cancer diagnostics market is segmented as:
Early-Stage Lung Cancer Diagnostics Market: Overview
The global early-stage lung cancer diagnostics market is expected to show significant growth over the forecast period, due to the rise in funding by governments for the development of novel drugs. According to GLOBOCAN, cancer burden has risen to 18.1 million cases and 9.6 million cancer deaths in 2017. GLOBOCAN also estimated that there have been 1.3 million cases of prostate cancer, worldwide, in 2017. By drug type, the polyketides segment is expected to gain the maximum market share, though polyketides will be the most preferred drug for apoptosis-inducing. The prostate cancer segment, by application, is expected to dominate the market by revenue, due to the high adoption of early-stage lung cancer diagnostics for the treatment of prostate cancer. Among all the distribution channels, the hospital pharmacies segment is expected to be the most dominant segment, whereas, the retail pharmacies segment is anticipated show a higher growth rate.
Early-Stage Lung Cancer Diagnostics Market: Regional Outlook
On the basis of geography, the early-stage lung cancer diagnostics market is classified into eight key regions, viz. North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, and the Middle East and Africa. North America is expected to dominate the global early-stage lung cancer diagnostics market, due to the rise in research and development for the development of novel drugs. Europe closely follows North America, due to the rising incidences of cancer in the region. The early-stage lung cancer diagnostics markets in APEJ and Japan are growing swiftly, owing to the rising number of contract research organizations in these regions. Latin America and the Middle East and Africa are the least lucrative regions for the early-stage lung cancer diagnostics market, due to the lack of awareness about the advanced therapies for the treatment of cancer among the people.
Early-Stage Lung Cancer Diagnostics Market: Key Players
Some of the key players found across the value chain of the early-stage lung cancer diagnostics market are BriaCell Therapeutics, Gilead Sciences, Inc., Cellectis S.A., Neon Therapeutics, Loxo Oncology, Bristol Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, Pfizer Inc., and AstraZeneca plc.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
